1. Home
  2. FATE vs NKTX Comparison

FATE vs NKTX Comparison

Compare FATE & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • NKTX
  • Stock Information
  • Founded
  • FATE 2007
  • NKTX 2015
  • Country
  • FATE United States
  • NKTX United States
  • Employees
  • FATE N/A
  • NKTX N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • NKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FATE Health Care
  • NKTX Health Care
  • Exchange
  • FATE Nasdaq
  • NKTX Nasdaq
  • Market Cap
  • FATE 116.5M
  • NKTX 123.5M
  • IPO Year
  • FATE 2013
  • NKTX 2020
  • Fundamental
  • Price
  • FATE $1.47
  • NKTX $2.30
  • Analyst Decision
  • FATE Hold
  • NKTX Strong Buy
  • Analyst Count
  • FATE 6
  • NKTX 5
  • Target Price
  • FATE $3.30
  • NKTX $13.50
  • AVG Volume (30 Days)
  • FATE 3.1M
  • NKTX 1.2M
  • Earning Date
  • FATE 11-11-2025
  • NKTX 11-06-2025
  • Dividend Yield
  • FATE N/A
  • NKTX N/A
  • EPS Growth
  • FATE N/A
  • NKTX N/A
  • EPS
  • FATE N/A
  • NKTX N/A
  • Revenue
  • FATE $8,470,000.00
  • NKTX N/A
  • Revenue This Year
  • FATE N/A
  • NKTX N/A
  • Revenue Next Year
  • FATE N/A
  • NKTX N/A
  • P/E Ratio
  • FATE N/A
  • NKTX N/A
  • Revenue Growth
  • FATE N/A
  • NKTX N/A
  • 52 Week Low
  • FATE $0.66
  • NKTX $1.31
  • 52 Week High
  • FATE $3.50
  • NKTX $4.55
  • Technical
  • Relative Strength Index (RSI)
  • FATE 62.81
  • NKTX 53.68
  • Support Level
  • FATE $1.30
  • NKTX $2.11
  • Resistance Level
  • FATE $1.65
  • NKTX $2.74
  • Average True Range (ATR)
  • FATE 0.17
  • NKTX 0.18
  • MACD
  • FATE 0.02
  • NKTX 0.03
  • Stochastic Oscillator
  • FATE 73.77
  • NKTX 39.58

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: